Aligos Therapeutics Announced Friday A Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos' Oligonucleotide Platform For Treatment Of Liver Diseases
Aligos Therapeutics Announced Friday A Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos' Oligonucleotide Platform For Treatment Of Liver Diseases
Aligos Therapeutics, Inc. (NASDAQ:ALGS, " Aligos" , the " Company" ))))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. ("Amoytop") for the use of Aligos' oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
Aligos Therapeutics, Inc.（纳斯达克股票代码：ALGS，“Aligos”，“公司”））是一家临床阶段的生物制药公司，专注于开发用于解决肝脏和病毒性疾病未得到满足的医疗需求的新疗法。该公司今天宣布，它已与厦门Amoytop Biotech有限公司签订了研究合作和开发协议。Ltd.（“Amoytop”）利用Aligos的寡核苷酸平台在大中华地区发现、研究和开发用于治疗肝脏疾病的寡核苷酸。
Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales.
根据协议条款，Aligos和Amoytop将合作研究和开发用于治疗肝脏疾病的寡核苷酸化合物。Amoytop 将获得独家许可，在大中华地区开发和商业化由此产生的产品，而 Aligos 将保留世界其他地区的版权。Aligos还将获得预付款和研究合作资金，并有资格获得总额高达1.09亿美元的许可产品的开发和销售里程碑补助金，以及净销售额的分级特许权使用费。